Abstract 5259

In this study, we attempted to determine the performance of the soluble fibrin monomer complex (SFMC) test in comparison to known activation markers, such as prothrombin fragment 1.2 (PF1.2), thrombin antithrombin complex (TAT) and d-dimer (DD). We have used the STA(R)-Liatest FM and STA(R)-Liatest D-Di kits to measure the SFMC and d-dimer levels.

A total of 25 patients were included in this study. The data and demographic information are shown in the table below.

IDGENDERAGEFMTATPF1.2D-dimer
1 M 66 0.42 2.3 1988 0.05 
2 F 31 27.93 >60.0 >12000 2.39 
3 F 24 3.41 14.1 1367 0.48 
4 F 61 2.22 7.7 335 0.63 
5 F 18 4.61 6.9 940 0.22 
6 F 38 156.52 43.5 >12000 10.37 
7 F 20 0.42 2.2 149 0.66 
8 F 21 0.42 2.4 143 0.24 
9 M 44 >150 15.4 11043 5.5 
10 F 42 3.4 <2.0 134 0.24 
11 M 46 0 4.8 271 0.3 
12 M 76 90.73 29.4 1712 >20.0 
13 F 61 3.41 3.8 484 0.52 
14 M 1 0.1 3.8 116 0.33 
15 F 33 4.2 37 6346 2.03 
16 F 35 3.2 2.6 325 0.09 
17 F 23 1.1 4.7 232 0.2 
18 M 64 2.3 2.6 189 0.15 
19 M 1 1.7 2.9 253 0.49 
20 M 64 2.2 33.2 451 2.43 
21 M 60 1.6 2.9 126 0.42 
22 F 55 2.2 2.6 189 0.97 
23 F 65 1.3 2.3 79 0.25 
24 F 39 3.6 8.1 222 0.18 
25 M 2 4.8 <2.0 109 0.53 
 Reference range >6.0 ug/mL <4 mcg/L 41–372 pmol/L <0.45 ug/mL 
IDGENDERAGEFMTATPF1.2D-dimer
1 M 66 0.42 2.3 1988 0.05 
2 F 31 27.93 >60.0 >12000 2.39 
3 F 24 3.41 14.1 1367 0.48 
4 F 61 2.22 7.7 335 0.63 
5 F 18 4.61 6.9 940 0.22 
6 F 38 156.52 43.5 >12000 10.37 
7 F 20 0.42 2.2 149 0.66 
8 F 21 0.42 2.4 143 0.24 
9 M 44 >150 15.4 11043 5.5 
10 F 42 3.4 <2.0 134 0.24 
11 M 46 0 4.8 271 0.3 
12 M 76 90.73 29.4 1712 >20.0 
13 F 61 3.41 3.8 484 0.52 
14 M 1 0.1 3.8 116 0.33 
15 F 33 4.2 37 6346 2.03 
16 F 35 3.2 2.6 325 0.09 
17 F 23 1.1 4.7 232 0.2 
18 M 64 2.3 2.6 189 0.15 
19 M 1 1.7 2.9 253 0.49 
20 M 64 2.2 33.2 451 2.43 
21 M 60 1.6 2.9 126 0.42 
22 F 55 2.2 2.6 189 0.97 
23 F 65 1.3 2.3 79 0.25 
24 F 39 3.6 8.1 222 0.18 
25 M 2 4.8 <2.0 109 0.53 
 Reference range >6.0 ug/mL <4 mcg/L 41–372 pmol/L <0.45 ug/mL 
View Large

The data indicate that in 16 out 25 patients, the SFMC levels are correlated with TAT and PF1.2. Only 3 out of 25 patients have elevated TAT and PF1.2 with normal SFMC levels. Therefore, our data would tend to indicate that SFMC level could be used as an activation marker to assess an ongoing prothrombotic process. In order to more fully determine the efficacy of the SFMC assay, we will obtain a detailed clinical history for the cases shown above.

Disclosures:

No relevant conflicts of interest to declare.

Topics:
fibrin, fibrin fragment d substance, antithrombin iii, antithrombins, florbetapir, prothrombin, thrombin, reference values

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2011 by The American Society of Hematology
2011
Sign in via your Institution